Harekala Hajabba, the orange seller who set up school for underprivileged, chosen for Padma Shri 2020

Bengaluru, Mar 16: A 23-year-old mobile app developer was arrested on Saturday for allegedly forging the signature of Infosys Foundation chairperson Sudha Murty to rope in Telugu actor Vijay Devarakonda as an app’s ambassador.

The arrest of Laveti Sai Krishna alias Krishna ML, a resident of Hyderabad, comes a year after the case was registered. Jayanagar police registered a case against Krishna on February 26, 2019 based on a complaint filed by Lt Col (retd) M Ramesh, representative of Infosys Foundation. The complaint was filed after the forged letter didn’t reach Devarakonda and came back to Infosys Foundation instead.

App developer is a B.Pharma holder

“We conducted an investigation and traced the app designer. We caught him and based on information provided by him, we learnt that Krishna was the brain behind the forged signature,” a senior police officer said.

Krishna confessed that he developed a mobile app — ‘Offer nearby’ — and planned to launch it in a big way. He wanted Telugu actor Vijay Devarakonda to be the app’s brand ambassador and tried contacting him. Krishna, however, was unable to meet Vijay.

Krishna then thought he could easily reach the actor if he sent a recommendation letter in the name of Sudha Murty.

“He forged the letterhead of Infosys Foundation and Sudha Murty’s signature. We are verifying his antecedents to know if he committed any other offence earlier,” said Rohini Sepat-Katoch, DCP (south). Rohini said Krishna is a B.Pharma holder and worked with an advertisement firm. Later, he planned to develop an app that provides details of offers for retail customers. He floated Laveti Technologies, and with help from a friend, developed ‘Offer nearby’.

As per the complaint, Krishna created a fake letterhead in the name of Sudha Murty and wrote to Devarakonda, asking him to become the brand ambassador/ partner for his mobile app. Krishna sent it through SpeedPost mentioning the sender’s address as Infosys Foundation. Krishna’s game was up when the letter, which wasn’t delivered to Devarakonda, came back to Infosys Foundation.

Bengaluru, June 12: The Karnataka government has withdrawn its notification that allowed factories to extend working hours up to 10 hours a day and 60 hours a week, with immediate effect.

The extension of work hours was from eight hours a day and 48 hours a week. On May 22, the government had exempted all the factories registered under the Factories Act, from the provisions of Section 51 (weekly hours) and Section 54 (daily hours), till August 21 subject to certain conditions.

"Whereas, having examined the provisions further, the Government of Karnataka now intends to withdraw the said notification," the state government in a fresh notification dated June 11 said.

It said, "Therefore, in exercise of the powers conferred under Section 5 of Factories Act, 1948 (Act No. 63 of 1948), the Government of Karnataka hereby withdraws the Notification dated 22-05-2020 with immediate effect."

According to the Karnataka Employers' Association, a petition was filed in the High Cour challenging the May 22 notification as "illegal, arbitrary and in violation" of Section 5 of the Factories Act which permits exemption from any of the provisions of the Factories Act only in case of Public Emergencies'.

During the course of hearing on June 11 an observation was made by the High Court, that it may have to quash the notification unless the government clarifies as to what is the 'Public Emergency' involved to enhance the working hours by exempting some provisions of the Factories Act, it said.

The court further observed that the government should make a submission on June 12 in this behalf. However, the government withdrew the notification on June 11 itself. Recently states like Rajasthan and Uttar Pradesh too had retracted after permitting extending work hours.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.